Sudden Cardiac Death in Heart Failure: A 20-Year Perspective from a Mediterranean Cohort.
暂无分享,去创建一个
M. Domingo | J. Lupón | A. Bayés‐Genís | G. Cediel | W. Levy | E. Zamora | R. de la Espriella | A. Aimo | E. Santiago‐Vacas | J. Santesmases | A. Sarrias | A. Borrellas | J. Núñez | P. Codina | Rafael de la Espriella | M. Ruiz‐Cueto | D. Casquete
[1] M. Domingo,et al. Relationship of Circulating Vegetable Omega-3 to Prognosis in Patients With Heart Failure. , 2022, Journal of the American College of Cardiology.
[2] J. M. Fernández,et al. Long-term secondary prevention of cardiovascular disease with a Mediterranean diet and a low-fat diet (CORDIOPREV): a randomised controlled trial , 2022, The Lancet.
[3] Deepak L. Bhatt,et al. Circulating linoleic acid at the time of myocardial infarction and risk of primary ventricular fibrillation , 2022, Scientific Reports.
[4] Akshay S. Desai,et al. Effect of sacubitril/valsartan on investigator‐reported ventricular arrhythmias in PARADIGM‐HF , 2021, European journal of heart failure.
[5] J. McMurray,et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. , 2021, European heart journal.
[6] P. Ponikowski,et al. Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF , 2021, European heart journal.
[7] W. Zareba,et al. Predicted benefit of an implantable cardioverter-defibrillator: the MADIT-ICD benefit score. , 2021, European heart journal.
[8] K. Fukuda,et al. Prediction of sudden cardiac death in Japanese heart failure patients: international validation of the Seattle Proportional Risk Model. , 2020, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[9] M. de Antonio,et al. A bio-clinical approach for prediction of sudden cardiac death in outpatients with heart failure: The ST2-SCD score. , 2019, International journal of cardiology.
[10] M. Domingo,et al. Trends in modes of death in heart failure over the last two decades: less sudden death but cancer deaths on the rise , 2019, European journal of heart failure.
[11] A. Brandes,et al. Risk Models for Prediction of Implantable Cardioverter-Defibrillator Benefit: Insights From the DANISH Trial. , 2019, JACC. Heart failure.
[12] Prashanthan Sanders,et al. Epidemiology of Sudden Cardiac Death: Global and Regional Perspectives. , 2019, Heart, lung & circulation.
[13] George A. Johnson,et al. Improving the Use of Primary Prevention Implantable Cardioverter-Defibrillators Therapy With Validated Patient-Centric Risk Estimates. , 2018, JACC. Clinical electrophysiology.
[14] M. de Antonio,et al. Dynamic Trajectories of Left Ventricular Ejection Fraction in Heart Failure. , 2018, Journal of the American College of Cardiology.
[15] S. Solomon,et al. Declining Risk of Sudden Death in Heart Failure , 2017, The New England journal of medicine.
[16] K. Swedberg,et al. Seattle Heart Failure and Proportional Risk Models Predict Benefit From Implantable Cardioverter-Defibrillators. , 2017, Journal of the American College of Cardiology.
[17] C. O'connor,et al. Does the Implantable Cardioverter-Defibrillator Benefit Vary With the Estimated Proportional Risk of Sudden Death in Heart Failure Patients? , 2017, JACC. Clinical electrophysiology.
[18] Hans Eiskjær,et al. Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure. , 2016, The New England journal of medicine.
[19] F. Khan,et al. Applicability of a risk score for prediction of the long-term benefit of the implantable cardioverter defibrillator in patients receiving cardiac resynchronization therapy. , 2016, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[20] D. Mozaffarian,et al. A novel method to predict the proportional risk of sudden cardiac death in heart failure: Derivation of the Seattle Proportional Risk Model. , 2015, Heart rhythm.
[21] Akshay S. Desai,et al. Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. , 2015, European heart journal.
[22] S. Priori,et al. Genetics of sudden cardiac death. , 2015, Circulation research.
[23] F. Gueyffier,et al. Beta-blockers for the prevention of sudden cardiac death in heart failure patients: a meta-analysis of randomized controlled trials , 2013, BMC Cardiovascular Disorders.
[24] J. McMurray,et al. Eplerenone in patients with systolic heart failure and mild symptoms. , 2011, The New England journal of medicine.
[25] L. Tavazzi,et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. , 2008, Lancet.
[26] Douglas L Packer,et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. , 2005, The New England journal of medicine.
[27] G. Billman,et al. Clinical prevention of sudden cardiac death by n-3 polyunsaturated fatty acids and mechanism of prevention of arrhythmias by n-3 fish oils. , 2003, Circulation.
[28] J. Oss,et al. PROPHYLACTIC IMPLANTATION OF A DEFIBRILLATOR IN PATIENTS WITH MYOCARDIAL INFARCTION AND REDUCED EJECTION FRACTION , 2002 .
[29] B. Pitt,et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.